FindTrial
Sign In

The use of systemic propranolol in congenital hemangiomas - CDO0901

The use of systemic propranolol in congenital hemangiomas - CDO0901

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2009-014571-49-IT
Enrollment
Unknown
Registered
2010-01-04
Start date
2010-01-15
Completion date
Unknown
Last updated
2014-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congenital hemangiomas MedDRA version: 12.1 Level: LLT Classification code 10018818 Term: Haemangioma congenital

Interventions

Product Name: propranololo sciroppo prodotto galenico Pharmaceutical Form: Syrup INN or Proposed INN: Propranolol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentrat

Sponsors

AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients > 4 weeks of age and =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - Hypersensitivity to propranolol in first degree relatives - Severe clinical conditions that contraindicate the inclusion in the study - Mellitus diabetes

Design outcomes

Primary

MeasureTime frame
Main Objective: The primary objective is to evaluate the efficacy of systemic propranolol in the treatment of congenital hemangiomas, during the first months of life.;Secondary Objective: The secondary objective is to evaluate the tolerability of systemic propranolol in the treatment of congenital hemangiomas, during the first months of life;Primary end point(s): Evaluation of the efficacy of systemic propranolol in the treatment of congenital hemangiomas, during the first months of life—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026